Prostate Cancer

  • David C. Smith
  • Donald L. Trump


Cancer is a significant problem in an elderly population. Among males no cancer is more prevalent than prostate cancer. In 1995 prostate cancer was the most commonly diagnosed cancer in the United States with an estimated 240,000 new cases.1 Prostate cancer was second only to lung cancer as a cause of cancer death in men in 1995, with an estimated 40,400 deaths. Cancer is second only to heart disease as a cause of death in adults, and prostate cancer accounts for one fifth of the cancer deaths in men over the age of 75. One of every eight men in the 60- to 79-year age group will be diagnosed with prostate cancer, as compared with one in 15 women of the same age who will be diagnosed with breast cancer. Although many patients with prostate cancer do not die as a consequence of their malignancy, a significant number require treatment of symptoms associated with the disease such as pain, bleeding, and urinary obstruction. Thus, prostate cancer is a major cause of mortality, morbidity, and health care expenditure in the elderly male population.


Prostate Cancer Radical Prostatectomy External Beam Radiotherapy Prostatic Carcinoma Spinal Cord Compression 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Wingo PA, Tong T, Bolden S. Cancer statistics, 1995. CA Cancer J Clin. 1995; 45: 8–30.PubMedCrossRefGoogle Scholar
  2. 2.
    Data from the Surveillance, Epidemiology, and End Results (SEER) Program Staff. Section III: Incidence. In: Cancer Statistics Review 1973–1986 Bethesda, MD: NIH; 1989:1IL45.Google Scholar
  3. 3.
    Carter HB, Coffey DS. The prostate: an increasing medical problem. Prostate. 1990; 16: 39–48.PubMedCrossRefGoogle Scholar
  4. 4.
    Carter BS, Bova GS, Beaty TH, et al. Hereditary prostate cancer: Epidemiologic and clinical features. J Urol. 1993; 150: 797–802.PubMedGoogle Scholar
  5. 5.
    Spitz MR, Currier RD, Fueger JJ, et al. Familial patterns of prostate cancer: a case-control analysis. J Urol. 1991; 146: 1305–1307.PubMedGoogle Scholar
  6. 6.
    Tulinius H, Egilsson V, Olafsdottir GH, et al. Risk of prostate, ovarian, and endometrial cancer among relatives of women with breast cancer. Br Med J. 1992; 305: 855857.Google Scholar
  7. 7.
    Thiessen EU. Concerning a familial association between breast cancer and both prostatic and uterine malignancies. Cancer. 1974; 34: 1102–1107.PubMedCrossRefGoogle Scholar
  8. 8.
    Arason A, Barkardottir RB, Egilsson V. Linkage analysis of chromosome 17q markers and breast-ovarian cancer in Icelandic families, and possible relationship to prostatic cancer. Am J Human Genet. 1993; 52: 711–717.Google Scholar
  9. 9.
    Collins VP, Kunimi K, Bergerheim U, et al. Molecular genetics and human prostatic carcinoma. Acta Oncol 1991; 30: 181–185.PubMedCrossRefGoogle Scholar
  10. 10.
    Sakr WA, Macoska JA, Benson P, et al. Allelic loss in locally metastatic, multisampled prostate cancer. Cancer Res. 1994;54:3273–3277 Google Scholar
  11. 11.
    Pienta KJ, Esper PS. Risk factors for prostate cancer. Ann Intern Med 1993; 118: 793–803.PubMedGoogle Scholar
  12. 12.
    Waterhouse J, Muir C, Shanmugaratnam K, et al. Cancer incidence in five continents. In: Anonymous Cancer Incidence. Lyon, France: International Agency for Research in Cancer; 1982.Google Scholar
  13. 13.
    Dunn JE. Cancer epidemiology in populations of the United States-with emphasis on Hawaii and California-and Japan. Cancer Res. 1975; 35: 3240–3245.PubMedGoogle Scholar
  14. 14.
    Shimizu H, Ross RK, Bernstein L, et al. Cancers of the prostate and breast among Japanese and white immigrants in Los Angeles county. Br J Cancer. 1991; 63: 963966.Google Scholar
  15. 15.
    Meikle AW, Smith JA, Jr. Epidemiology of prostate cancer. Urology Clin North Am. 1990; 17: 709–718.Google Scholar
  16. 16.
    Giovannucci E, Rimm EB, Colditz GA, et al. A prospective study of dietary fat and risk of prostate cancer. J Natl Cancer Inst. 1993; 85: 1571–1579.PubMedCrossRefGoogle Scholar
  17. 17.
    Hayes RB, Bogdanovicz JF, Schroeder FH, et al. Serum retinol and prostate cancer. Cancer. 1988; 62: 2021–2026.PubMedCrossRefGoogle Scholar
  18. 18.
    Schwartz GG, Hulka BS. Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis). Anticancer Res. 1990; 10: 1307–1312.PubMedGoogle Scholar
  19. 19.
    Bennett CL, Greenfield S, Aronow H, et al. Patterns of care related to age of men with prostate cancer. Cancer. 1991; 67: 2633–2641.PubMedCrossRefGoogle Scholar
  20. 20.
    Cook GB, Watson FR. A comparison by age of death rates due to prostate cancer alone. J Urol. 1968; 100: 669671Google Scholar
  21. 21.
    Smedley HM, Sinnott M, Freedman LS, et al. Age and survival in prostatic carcinoma. Br J Urol. 1983; 55: 529533.Google Scholar
  22. 22.
    Ishigawa S, Soloway MS, Van Der Zwaag R, et al. Prognostic factors in survival free of progression after androgen deprivation therapy for treatment of prostate cancer. J Urol. 1988; 141: 1139–1142.Google Scholar
  23. 23.
    Chodak GW, Vogelzang NJ, Caplan RJ, et al. Independent prognostic factors in patients with metastatic (stage D2) prostate cancer. DAMA. 1991; 265: 618–621.Google Scholar
  24. 24.
    Johansson JE, Andersson SO, Holmberg L, et al. Prognostic factors in progression-free survival and corrected survival in patients with advanced prostatic cancer: results from a randomized study comprising 150 patients treated with orchiectomy or estrogens. J Urol. 1991; 146: 1327 1333.Google Scholar
  25. 25.
    Emrich LJ, Priore RL, Murphy GP, et al. Prognostic factors in patients with advanced stage prostate cancer. Cancer Res. 1985; 45: 5173–5179.PubMedGoogle Scholar
  26. 26.
    Kramer BS, Brown ML, Prorok PC, et al. Prostate cancer screening: what we know and what we need to know. Ann Intern Med. 1993; 119: 914–923.PubMedGoogle Scholar
  27. 27.
    Gann PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. DAMA. 1995; 273: 289–294.Google Scholar
  28. 28.
    Stamey TA, Yang N, Hay AR, et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 1987; 317: 909–916.PubMedCrossRefGoogle Scholar
  29. 29.
    Chybowski FM, Keller JJ, Bergstralh EJ, et al. Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters. J Urol. 1991; 145: 313–318.PubMedGoogle Scholar
  30. 30.
    Whitmore WF. Hormone therapy in prostatic cancer. Am J Med. 1956; 21: 697–713.PubMedCrossRefGoogle Scholar
  31. 31.
    Jewett HJ. The present status of radical prostatectomy for stage A and B prostatic cancer. Urol Clin North Am. 1975; 2: 105–124.PubMedGoogle Scholar
  32. 32.
    Montie JE. 1992 staging system for prostate cancer. Semin Urol. 1993; 11: 10–13.PubMedGoogle Scholar
  33. 33.
    Gleason DF. Classification of prostatic carcinomas. Cancer Chemother Rep. 1966; 50: 125.PubMedGoogle Scholar
  34. 34.
    Partin AW, Steinberg GD, Pitcock RV, et al. Use of nuclear morphometry, Gleason histologic scoring, clinical stage, and age to predict disease-free survival among patients with prostate cancer. Cancer. 1992; 70: 161–168.PubMedCrossRefGoogle Scholar
  35. 35.
    Partin AW, Yoo J, Carter HB, et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol. 1993; 150: 110–114X.PubMedGoogle Scholar
  36. 36.
    McGowan DG, Bain GO, Hanson J. Evaluation of histological grading (Gleason) in carcinoma of the prostate: adverse influence of highest grade. Prostate. 1983; 4: 11 1118.Google Scholar
  37. 37.
    Chodak GW, Thisted RA, Gerber GS, et al. Results of conservative management of clinically localized prostate cancer. N Engl J Med. 1994; 330: 242–248.PubMedCrossRefGoogle Scholar
  38. 38.
    Catalona WJ. Management of cancer of the prostate. N Engl J Med. 1994; 331: 996–1004.PubMedCrossRefGoogle Scholar
  39. 39.
    Fowler FJ Jr, Barry MJ, Lu-Yao G, et al. Patient reported complications and follow up treatment after radical prostatectomy: The National Medicare Experience: 19881990. Urology. 1993; 42: 622–629.PubMedCrossRefGoogle Scholar
  40. 40.
    Paulson DF, Lin GH, Hinshaw W, et al. Radical surgery versus radiotherapy for adenocarcinoma of the prostate. J UroL 1981; 128: 502–503.Google Scholar
  41. 41.
    Byar DP, Corle DK. VACURG randomized trial of radical prostatectomy for stages I and II prostate cancer. Urology Suppl. 1981; 17: 7–11.Google Scholar
  42. 42.
    Madsen PO, Graversen PH, Gasser TC, et al. Treatment of localized prostatic cancer. Radical prostatectomy versus placebo. A 15-year follow-up. Scand J Urol Nephrol Suppl. 1988; 110: 95–100.PubMedGoogle Scholar
  43. 43.
    Epstein JI, Paull G, Eggleston JC, et al. Prognosis of untreated stage Al prostatic carcinoma: a study of 94 cases with extended followup. J UroL 1986; 136: 837–839.PubMedGoogle Scholar
  44. 44.
    George NJR. Natural history of localised prostatic cancer managed by conservative therapy alone. Lancet. 1988; 1: 494–497.PubMedCrossRefGoogle Scholar
  45. 45.
    Adolfsson J, Ronstrom L, Carstensen J, et al. The natural course of low grade, non-metastatic prostatic carcinoma. Br J Urol. 1990; 65: 611–614.PubMedCrossRefGoogle Scholar
  46. 46.
    Zhang G, Wasserman NF, Sidi AA, et al. Long-term follow-up results after expectant management of stage Al prostatic cancer. J Urol. 1991; 146: 99–103.PubMedGoogle Scholar
  47. 47.
    Whitmore WF Jr, Warner JA, Thompson IM. Expectant management of localized prostatic cancer. Cancer. 1991; 67: 1091–1096.PubMedCrossRefGoogle Scholar
  48. 48.
    Adolfsson J, Carstensen J, Lowhagen T. Deferred treatment in clinically localised prostatic carcinoma. Br J Urol. 1992; 69: 183–187.PubMedCrossRefGoogle Scholar
  49. 49.
    Johansson JE. Expectant management of early stage prostatic cancer: Swedish experience. J Urol. 1994; 152: 1753 1756.Google Scholar
  50. 50.
    Paulson DF, Moul JW, Walther PJ. Radical prostatectomy for clinical stage T1–2NOMO prostatic adenocarcinoma: long term results. J Urol. 1990; 144: 1180–1184.PubMedGoogle Scholar
  51. 51.
    Hanks GE. External beam radiation treatment for prostate cancer: still the gold standard. Oncology. 1992; 6: 7994.Google Scholar
  52. 52.
    Onik GM, Cohen JK, Reyes GD, et al. Transrectal ultrasound-guided percutaneous radical cryosurgical ablation of the prostate. Cancer. 1993; 72: 1291–1299.PubMedCrossRefGoogle Scholar
  53. 53.
    Schroeder FH, Belt E. Carcinoma of the prostate: a study of 213 patients with stage C tumors treated by total perineal prostatectomy. J Urol. 1974; 114: 257260.Google Scholar
  54. 54.
    Zagars GK, von Eschenback AC, Johnson DE, et al. Stage C adenocarcinoma of the prostate. An analysis of 551 patients treated with external beam radiation. Cancer. 1987; 60: 1489–1499.PubMedCrossRefGoogle Scholar
  55. 55.
    Gee WF, Cole JR. Symptomatic stage C carcinoma of the prostate. Traditional therapy. Urology. 1980; 15: 335–337.PubMedCrossRefGoogle Scholar
  56. 56.
    Zincke H, Utz DC, Taylor WF. Bilateral pelvic lymphadenectomy and radical prostatectomy for clinical stage C prostatic cancer: role of adjuvant treatment for residual cancer and in disease progression. J UroL 1985; 135: 1199–1205.Google Scholar
  57. 57.
    Paulson DF, Hodge GB Jr, Hinshaw W. Radiation therapy versus delayed androgen deprivation for stage C carcinoma of the prostate. J Urol. 1984; 131: 901–902.PubMedGoogle Scholar
  58. 58.
    Gibbons RP, Cole BS, Richardson RG, et al. Adjuvant radiotherapy following radical prostatectomy: results and complications. J UroL 1986; 135: 65–68.PubMedGoogle Scholar
  59. 59.
    Kramer SA, Cline WA, Farnham R, et al. Prognosis of patients with stage D1 prostatic adenocarcinoma. J Urol. 1981; 125: 817–819.PubMedGoogle Scholar
  60. 60.
    Steinberg GD, Epstein JI, Piantadosi S, et al. Management of stage D1 adenocarcinoma of the prostate: The Johns Hopkins experience 1974 to 1987. J Urol. 1990; 144: 1425 1431.Google Scholar
  61. 61.
    Cheng CW, Bergstralh EJ, Zincke H. Stage Dl prostate cancer. A nonrandomized comparison of conservative treatment options versus radical prostatectomy. Cancer. 1993; 71: 996–1004.PubMedCrossRefGoogle Scholar
  62. 62.
    Scardino PT, Weaver R, Hudson MA. Early detection of prostate cancer. Hum Pathol 1992; 23: 211–222.PubMedCrossRefGoogle Scholar
  63. 63.
    Huggins C, Hodges CV. Studies on prostatic cancer: the effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941; 1: 293–297.Google Scholar
  64. 64.
    The Leuprolide Study Group. Leuprolide versus diethylstilbestrol for metastatic prostate cancer. N Engl J Med. 1984; 311: 1281–1286.Google Scholar
  65. 65.
    Peeling WB. Phase III studies to compare goserelin (Zoladex) with orchiectomy and with diethylstilbestrol in treatment of prostatic cancer. Urology. 1989; 33: 45–52.PubMedCrossRefGoogle Scholar
  66. 66.
    De Voogt HJ, Smith PH, Pavone-Macaluso M, et al. Cardiovascular side effects of diethylstilbestrol, cyproterone acetate, medroxyprogesterone acetate and estramustine phosphate used for the treatment of advanced prostatic cancer: results from European organization for research on treatment of cancer trials 30761 and 30762. J Urol. 1986; 135: 303–307.PubMedGoogle Scholar
  67. 67.
    Lin BJ, Chen KK, Chen MT, et al. The time for serum testosterone to reach castrate level after bilateral orchiectomy or oral estrogen in the management of metastatic prostatic cancer. Urology. 1994; 43: 834–837.PubMedCrossRefGoogle Scholar
  68. 68.
    Ahmann FR, Citrin DL, De Haan HA, et al. Zoladex: a sustained-release, monthly luteinizing hormone-releasing hormone analogue for the treatment of advanced prostate cancer. J Clin Oncol. 1987; 5: 912–917.PubMedGoogle Scholar
  69. 69.
    Bennett CL, McLeod DG, Hillner BE. Estimating the cost-effectiveness of total androgen blockade (TAB) for stage D-2 prostate cancer (meeting abstract) Proc Ann Meet Am Soc Clin Oncol. 1994;13 Google Scholar
  70. 70.
    Warner B, Worgul TJ, Drago J, et al. Effect of very high dose D-leucine6-gonadotropin-releasing hormone proethylamide on the hypothalamic-pituitary testicular axis in patients with prostatic cancer. Clin Invest. 1983; 71: 1842 1853.Google Scholar
  71. 71.
    Schulze H, Senge T. Influence of different types of antiandrogens on luteinizing hormone-releasing hormone analogue-induced testosterone surge in patients with metastatic carcinoma of the prostate. J Urol. 1990; 144: 934–941.PubMedGoogle Scholar
  72. 72.
    Labrie F, Dupont A, Belanger A, et al. New approach in the treatment of prostate cancer: complete instead of partial withdrawal of androgens. Prostate. 1983; 4: 579594.Google Scholar
  73. 73.
    Crawford ED, Eisenberger MA, McLeod DG, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med. 1989; 321: 419–424.PubMedCrossRefGoogle Scholar
  74. 74.
    Tyrrell CJ, Altwein JE, Klippel F, et al. A multicenter randomized trial comparing the luteinizing hormone-releasing hormone analogue goserelin acetate alone and with flutamide in the treatment of advanced prostate cancer. J Urol. 1991; 146: 1321–1326.PubMedGoogle Scholar
  75. 75.
    Nicol DL, Heathcote PS, Kateley GD, et al. Advanced prostate cancer. The role of high priced hormone therapy. Med J Aust. 1993; 159: 16–19.PubMedGoogle Scholar
  76. 76.
    Wysowski DK, Freiman JP, Tourtelot JB, et al. Fatal and nonfatal hepatotoxicity associated with flutamide. Ann Intern Med. 1993;118:860–864 Google Scholar
  77. 77.
    Kelly WK, Scher HI. Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. J Urol. 1993; 149: 607–609.PubMedGoogle Scholar
  78. 78.
    Dupont A, Gomez JL, Cusan L, et al. Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy. J Urol. 1993; 150: 908913.Google Scholar
  79. 79.
    Small EJ, Carroll PR. Prostate-specific antigen decline after casodex withdrawal: evidence for an antiandrogen withdrawal syndrome. Urology. 1994; 43: 408–410.PubMedCrossRefGoogle Scholar
  80. 80.
    Smith DC, Bahnson RR, Trump DL. Secondary hormonal manipulation (prostate cancer). In: Vogelzang NJ, Scardino PT, Shipley WU, et al., eds. Comprehensive Textbook of Genitourinary Oncology. Baltimore: Williams & Wilkins; 1995.Google Scholar
  81. 81.
    Loprinzi CL, Ellison NM, Goldberg RM, et al. Alleviation of cancer anorexia and cachexia: studies of the Mayo Clinic and the North Central Cancer Treatment Group. Semin Oncol. 1990; 17: 8–12.PubMedGoogle Scholar
  82. 82.
    Eisenberger M. How effective is cytotoxic chemotherapy for disseminated prostatic cancer. Oncology. 1987; 1: 59.PubMedGoogle Scholar
  83. 83.
    Eisenberger MA, Simon R, O’Dwyer PJ, et al. A reevaluation of nonhormonal cytotoxic chemotherapy in treatment of prostatic carcinoma.J Clin Oncol. 1985;3:827–841 Google Scholar
  84. 84.
    Yagoda A, Petrylak D. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer. 1993; 71: 1098–1109.PubMedCrossRefGoogle Scholar
  85. 85.
    Tannock IF. Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate? J Clin Oncol. 1985;3:1013-1021 Google Scholar
  86. 86.
    Hudes GR, Greenberg R, Krigel RL, et al. Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer J Clin Oncol. 1992;10:1754–1761 Google Scholar
  87. 87.
    Seidman AD, Scher HI, Petrylak D, et al. Estramustine and vinblastine: use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer. J Urol. 1992; 147: 931–934.PubMedGoogle Scholar
  88. 88.
    Pienta KJ, Redman B, Hussain M, et al. Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate J Clin Oncol. 1994;12:2005–2012 Google Scholar
  89. 89.
    Myers CE, Cooper MR, La Rocca R, et al. Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer J Clin Oncol. 1992;10:881–889 Google Scholar
  90. 90.
    Eisenberger MA, Reyno LM, Jodrell DI, et al. Suramin, an active drug for prostate cancer: interim observations in a phase I trial. J Natl Cancer Inst. 1993; 85: 611–621.PubMedCrossRefGoogle Scholar
  91. 91.
    Trump D, Smith DC, Adedoyin A, et al. All-trans retinoic acid (ATRA) in hormone refractory prostate Cancer (HRPC): ineffectiveness due to failure of drug delivery Proc Am Soc Clin Oncol. 1994;13:241 Google Scholar
  92. 92.
    Sanda MG, Ayyagari SR, Jaffee EM, et al. Demonstration of a rational strategy for human prostate cancer gene therapy. J Urol. 1994; 151: 622–628.PubMedGoogle Scholar
  93. 93.
    Skowronski RJ, Peehl DM, Feldman D. Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. Endocrinology. 1993; 132: 1952–1960.PubMedCrossRefGoogle Scholar
  94. 94.
    Flynn DF, Shipley WU. Management of spinal cord compression secondary to metastatic prostatic carcinoma. Urol Clin North Am. 1991;18:145–152 Google Scholar
  95. 95.
    Vecht CJ, Haaxma-Reiche H, van Putten WLJ, et al. Initial bolus of conventional versus high-dose dexamethasone in metastatic spinal cord compression Neurology. 1989;39:1255–1257 Google Scholar
  96. 96.
    Smith EM, Hampel N, Ruff RL, et al. Spinal cord compression secondary to prostate carcinoma: treatment and prognosis. J Urol. 1993; 149: 330–333.PubMedGoogle Scholar
  97. 97.
    Shoskes DA, Perrin RG. The role of surgical management for symptomatic spinal cord compression in patients with metastatic prostate cancer. J Urol. 1989; 142: 337–339.Google Scholar
  98. 98.
    Dijstra S, Wiggers T, van Geel BN, et al. Impending and actual pathological fractures in patients with bone metastases of the long bones. A retrospective study of 233 surgically treated fractures. Eur J Surg. 1994; 160: 535–542.PubMedGoogle Scholar
  99. 99.
    Nielsen OS, Munro AJ, Tannock IF. Bone metastases: Pathophysiology and management policy. J Clin Oncol. 1991; 9: 509–524.PubMedGoogle Scholar
  100. 100.
    Hardman PD, Robb JE, Kerr GR, et al. The value of internal fixation and radiotherapy in the management of upper and lower limb bone metastases. Clin Oncol (R Coll Radiol). 1992; 4: 244–248.CrossRefGoogle Scholar
  101. 101.
    Ashburn MA, Lipman AG. Management of pain in the cancer patient. Anesth Analg. 1993; 76: 402–416.PubMedGoogle Scholar
  102. 102.
    Cleeland CS, Gonin R, Hatfield AK, et al. Pain and its treatment in outpatients with metastatic cancer. N Engl J Med. 1994;330:592–596 Google Scholar
  103. 103.
    Cherny NI, Portnoy RK. The management of cancer pain. CA Cancer J Clin. 1994; 44: 263–303.PubMedCrossRefGoogle Scholar
  104. 104.
    Hammack JE, Loprinzi CL. Use of orally administered opioids for cancer-related pain. Mayo Clin Proc. 1994; 69: 384–390.PubMedCrossRefGoogle Scholar
  105. 105.
    Eisenberger E, Berkey CS, Carr DB, et al. Efficacy and safety of nonsteroidal antiinflammatory drugs for cancer pain: A meta-analysis.J Clin Oncol. 1994;12:2756–2765 Google Scholar
  106. 106.
    Kantor TG. Control of pain by nonsteroidal anti-inflammatory drugs. Med Clin of North America. 1982; 66: 1053–1059.Google Scholar
  107. 107.
    Benson RC, Jr., Hasan SM, Jones AG, et al. External beam radiotherapy for palliation of pain from metastatic carcinoma of the prostate. J Urol. 1981; 127: 69–71.Google Scholar
  108. 108.
    Gilbert HA, Kagan AR, Nussbaum H, et al. Evaluation of radiation therapy for bone metastases: pain relief and quality of life. Am J Roentgenol. 1977; 129: 1095–1096.CrossRefGoogle Scholar
  109. 109.
    Robinson RG, Preston DF, Spicer JA, et al. Radionuclide therapy of intractable bone pain: emphasis on strontium-89. Semin Nucl Med. 1992; 22: 28–32.PubMedCrossRefGoogle Scholar
  110. 110.
    Maxon FR III, Schroder LE, Hertzberg VS, et al. Rhenium-186(Sn)HEDP for treatment of painful osseous metastases: results of a double-blind crossover comparison with placebo. J Nucl Med. 1991; 32: 1877–1881.PubMedGoogle Scholar
  111. 111.
    Collins C, Eary JF, Donaldson G, et al. Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: a phase I/II trial J Nucl Med. 1993;34:1839–1844 Google Scholar
  112. 112.
    Purohit OP, Anthony C, Radstone CR, et al. High-dose intravenous pamidronate for metastatic bone pain. Br J Cancer. 1994;70:554–558 Google Scholar
  113. 113.
    Thurlimann B, Morant R, Jungi WF. Pamidronate (APD) for bone pain: final results of a dose-effect study. Proc ASCO. 1992; 11.Google Scholar
  114. 114.
    Adami S, Mian M. Clodronate therapy of metastatic bone disease in patients with prostatic carcinoma. Recent Results Cancer Res. 1989;116:67–72 Google Scholar
  115. 115.
    Eisenhut M, Berberich R, Kimmig B, et al. Iodine131-labeled diphosphonates for palliative treatment of bone metastases: II. Preliminary clinical results with iodine-131 BDP3. J Nucl Med. 1986; 27: 1255–1261.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1997

Authors and Affiliations

  • David C. Smith
  • Donald L. Trump

There are no affiliations available

Personalised recommendations